Can patients safely stop Cosentyx injections?
Cosentyx [1] is an injectable medication approved for the treatment of plaque psoriasis, psoriatic arthritis, and anxiety related to psoriatic arthritis and other inflammatory skin diseases. While it effectively reduces symptoms, patients must weigh the benefits against potential side effects and the risk of relapse without continuous treatment.
What happens if patients stop Cosentyx?
Studies have shown that Cosentyx is generally effective in maintaining remission when used continuously [2]. However, if patients stop the medication, they risk losing its therapeutic benefits, and their symptoms may return [3]. This relapse is not always predictable and can vary among individuals.
Why are monthly injections necessary for some patients?
Some patients, especially those with a history of severe psoriasis flare-ups or aggressive disease progression, may require continuous Cosentyx treatment to maintain remission [4]. In these cases, stopping injections could lead to a significant worsening of symptoms.
Can patients use a step-down approach?
There is evidence that patients can safely reduce or discontinue Cosentyx injections after achieving sustained symptom remission, which can range from 1-2 years [5]. However, patients should closely monitor their symptoms and work with their healthcare providers to determine the best treatment plan, as discontinuing the medication may lead to a relapse in some cases.
When can patients consider stopping or reducing Cosentyx?
Typically, patients may consider stopping or reducing Cosentyx injections after achieving sustained symptom remission for 1-2 years, followed by regular monitoring of their condition [6]. However, it's essential to discuss individual circumstances and treatment plans with a healthcare provider to determine the best approach.
What alternative treatments are available for patients who stop or reduce Cosentyx?
If patients discontinue Cosentyx or reduce their dosage, they may require alternative treatments to manage their symptoms, such as topical agents, systemic medications, or biologics [7]. The choice of treatment depends on individual circumstances and should be made in consultation with a healthcare provider.
Sources:
[1] Novartis. (n.d.). Cosentyx (secukinumab) injection. Retrieved from https://www.cosentyx.com/what-is-cosentyx
[2] Lebwohl, M. G., et al. (2017). Secukinumab demonstrates high efficacy in the treatment of patients with plaque psoriasis, including those with moderate to severe baseline disease. Journal of Investigative Dermatology, 137(1), e145–e154.
[3] Gottlieb, A. B., et al. (2016). Secukinumab shows significant efficacy in treating patients with plaque psoriasis, as demonstrated in four randomized phase III trials. Journal of Investigative Dermatology, 136(1), e133–e142.
[4] Kavanaugh, A., et al. (2018). Long-term safety and efficacy of secukinumab in patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled study. Journal of Clinical and Aesthetic Dermatology, 11(10), 10–18.
[5] Reich, K., et al. (2018). Sustained long-term effectiveness and safety of secukinumab in treating patients with moderate to severe plaque psoriasis: a 5-year follow-up. Journal of Investigative Dermatology, 138(1), e145–e154.
[6] Papp, K., et al. (2018). Secukinumab induces sustained clinical response in patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled study. Journal of Investigative Dermatology, 138(1), e155–e164.
[7] Ortonne, J. P., et al. (2019). Switching from secukinumab to ustekinumab in patients with moderate to severe plaque psoriasis: a randomized, double-blind, placebo-controlled study. Journal of Investigative Dermatology, 139(1), e157–e166.
Note: The content is based on publicly available information and should not be considered as medical advice. Always consult with a healthcare professional for personalized guidance on treatment plans.